Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Hepatobiliary Diseases News

News
Durvalumab Plus Chemo Reduced Risk of Death in Advanced BTC
10/26/2022
The new immunotherapy agent durvalumab combined with chemotherapy showed statistically significant reduction in the risk of death vs chemotherapy alone in the TOPAZ-1 trial.
The new immunotherapy agent durvalumab combined with chemotherapy showed statistically significant reduction in the risk of death vs chemotherapy alone in the TOPAZ-1 trial.
The new immunotherapy agent...
10/26/2022
Gastroenterology
News
Do Gallstones Predict Biliary Tract Cancers?
10/14/2022
Investigators conducted a systematic review to find out if gallstones are associated with the later development of biliary tract cancers.
Investigators conducted a systematic review to find out if gallstones are associated with the later development of biliary tract cancers.
Investigators conducted a...
10/14/2022
Gastroenterology

Advertisement

News
CCA Association With Occupations Examined
10/11/2022
Researchers delved into the hypothesis that some jobs may place workers at higher risk of developing cholangiocarcinoma by conducting a systematic review of past cases related to occupation.
Researchers delved into the hypothesis that some jobs may place workers at higher risk of developing cholangiocarcinoma by conducting a systematic review of past cases related to occupation.
Researchers delved into the...
10/11/2022
Gastroenterology
News
Durvalumab Could Boost Standard of Care for Biliary Tract Cancer
09/19/2022
The TOPAZ-1 phase 3 study tested durvalumab plus chemotherapy vs placebo combined with chemotherapy among patients with advanced biliary tract cancer.
The TOPAZ-1 phase 3 study tested durvalumab plus chemotherapy vs placebo combined with chemotherapy among patients with advanced biliary tract cancer.
The TOPAZ-1 phase 3 study tested...
09/19/2022
Gastroenterology
News
FDA Approves Durvalumab for Biliary Tract Cancer
09/06/2022
The agency okays the use of durvalumab with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer.
The agency okays the use of durvalumab with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer.
The agency okays the use of...
09/06/2022
Gastroenterology

Advertisement

News
Early Laparoscopic Cholecystectomy Achieves Best Outcomes
08/07/2022
Most patients with acute cholecystitis experience fewer complications if they have laparoscopic cholecystectomy with 3 days of diagnosis, research shows.
Most patients with acute cholecystitis experience fewer complications if they have laparoscopic cholecystectomy with 3 days of diagnosis, research shows.
Most patients with acute...
08/07/2022
Gastroenterology
News
Statin Use Associated With Lower HCC Risk
07/05/2022
Patients with chronic hepatitis B or C had a significantly lower risk of developing hepatocellular carcinoma if they received statin therapy, researchers found.
Patients with chronic hepatitis B or C had a significantly lower risk of developing hepatocellular carcinoma if they received statin therapy, researchers found.
Patients with chronic hepatitis...
07/05/2022
Gastroenterology
News
Risks of HCC Gauged Among Patients With NAFLD-Related Cirrhosis
12/14/2012
Investigators sought to assess the risk of hepatocellular carcinoma among patients with cirrhosis related to nonalcoholic fatty liver disease compared to those with cirrhosis from other causes.
Investigators sought to assess the risk of hepatocellular carcinoma among patients with cirrhosis related to nonalcoholic fatty liver disease compared to those with cirrhosis from other causes.
Investigators sought to assess...
12/14/2012
Gastroenterology

Advertisement

News
Durvalumab-Tremelimumab Combo Noninferior to Comparable HCC First-Line Therapies
11/15/2012
A literature review showed that the combination of atezolizumab plus bevacizumab was not statistically superior to durvalumab plus tremelimumab in reducing mortality among patients with unresectable hepatocellular carcinoma.
A literature review showed that the combination of atezolizumab plus bevacizumab was not statistically superior to durvalumab plus tremelimumab in reducing mortality among patients with unresectable hepatocellular carcinoma.
A literature review showed that...
11/15/2012
Gastroenterology

Advertisement

Advertisement

Advertisement

Advertisement

Sign up for our e-Newsletters

Gastroenterology Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

News

News
Novel AI System Shows Success in Detection of Adenomas
08/27/2024
CAD-EYE detection system significantly improved the number of adenomas detected per colonoscopy without extending the procedure time, according to a recent report.
CAD-EYE detection system significantly improved the number of adenomas detected per colonoscopy without extending the procedure time, according to a recent report.
CAD-EYE detection system...
08/27/2024
Gastroenterology
News
Implementation of Fecal Immunochemical Test-Based Program in Colorectal Cancer Screening
08/20/2024
Investigators studied whether fecal immunochemical test programs might be feasible options for improving colorectal cancer screening in areas with limited resources.
Investigators studied whether fecal immunochemical test programs might be feasible options for improving colorectal cancer screening in areas with limited resources.
Investigators studied whether...
08/20/2024
Gastroenterology
News
Low-Dose Aspirin and Prevention of Colorectal Cancer
08/14/2024
Results of a new study showed that low-dose aspirin use is associated with a lower risk of colorectal cancer.
Results of a new study showed that low-dose aspirin use is associated with a lower risk of colorectal cancer.
Results of a new study showed...
08/14/2024
Gastroenterology
News
FIT Screening Associated With Lower Risk of Death From CRC
08/06/2024
Findings of a new study support the role of fecal immunochemical testing in reducing mortality from colorectal cancer, researchers report.
Findings of a new study support the role of fecal immunochemical testing in reducing mortality from colorectal cancer, researchers report.
Findings of a new study support...
08/06/2024
Gastroenterology
FDA
News
FDA Approves First Blood Test for Primary CRC Screening
07/30/2024
Shield is the first blood test cleared for primary colorectal cancer screening that meets Medicare performance requirements.
Shield is the first blood test cleared for primary colorectal cancer screening that meets Medicare performance requirements.
Shield is the first blood test...
07/30/2024
Gastroenterology
News
Colorectal Cancer Risk Higher Among Patients WIth PSC, With or Without IBD
07/24/2024
Extended screening and surveillance are recommended for all patients with primary sclerosing cholangitis, but those with comorbid inflammatory bowel disease are at highest risk.
Extended screening and surveillance are recommended for all patients with primary sclerosing cholangitis, but those with comorbid inflammatory bowel disease are at highest risk.
Extended screening and...
07/24/2024
Gastroenterology
News
Ultraprocessed Food Linked to Elevated Risk of CRC
07/24/2024
C olorectal cancer, colon cancer, and noncardia gastric cancer were found to be associated with high consumption of ultraprocessed foods, according to recent research.
C olorectal cancer, colon cancer, and noncardia gastric cancer were found to be associated with high consumption of ultraprocessed foods, according to recent research.
C olorectal cancer, colon...
07/24/2024
Gastroenterology
FDA alert
News
FDA Permits Marketing of First Point-of-Care Hepatitis C RNA Test
06/28/2024
The device can provide results in an hour from a fingertip blood test.
The device can provide results in an hour from a fingertip blood test.
The device can provide results...
06/28/2024
Gastroenterology
FDA alert
FDA Alert
Elafibranor Receives Accelerated FDA Approval for PBC
06/14/2024
The first-in-class PPAR is the first new medicine approved in nearly a decade for primary biliary cholangitis.
The first-in-class PPAR is the first new medicine approved in nearly a decade for primary biliary cholangitis.
The first-in-class PPAR is the...
06/14/2024
Gastroenterology
News
Biomarker Study Finds ‘Clearcut’ Case for Early Advanced Therapy for CD
05/24/2024

Jolynn Tumolo

Jolynn Tumolo
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly...
05/24/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use